RxDoctor Payments Data

Kathleen Maksimowicz McKinnon, DO

Rheumatology · Detroit, MINPI 1922072602

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $21,275 of the $25,678 with a category attached, or 82.9%. 8 manufacturers reported payments, led by Amgen at 34.8% of the total. Reporting peaked in 2019 at $8,910 and has fallen 84.3% since, to $1,397 in 2025.

$25,678in general payments, 2019–2025

Across 45 payments — averaging $570.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$9K
  • Pfizer$5K
  • AstraZeneca$4K
  • GSK$4K
  • AbbVie$2K
  • NS Pharma, Inc.$984
  • plus $322 from 2 others
$817,113in research payments, 2019–2025

Across 81 payments — averaging $10,088 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$456K
  • NS Pharma, Inc.$98K
  • E.r. Squibb & Sons, L.L.C.$75K
  • Eli Lilly$70K
  • GSK$47K
  • AbbVie$31K
  • plus $41K from 3 others

What the payments were for

  • Consulting fees$21,27583%
  • Travel & lodging$2,3519%
  • Food & beverage$2,0528%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen15$8,931
Pfizer5$5,230
AstraZeneca9$4,139
GSK2$3,701
AbbVie8$2,372
NS Pharma, Inc.4$984
E.r. Squibb & Sons, L.L.C.1$301
Radius Health, Inc.1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,678 in reported general payments places this provider in the 85th percentile of 195 rheumatology providers in Michigan.

See all rheumatology providers in Michigan

Medicare billing

Part B allowed, 2024
$21,989
Medicare patients
80
Services billed
269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Actemra ActpenTocilizumab25$121,495
RinvoqUpadacitinib12$77,569
Prednisone72$709
MethotrexateMethotrexate Sodium29$577
Gabapentin14$234
Omeprazole11$187
Pregabalin20$119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$2,372$77,56912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 195 rheumatology providers in Michigan.

Other rheumatology in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →